EUVIMEDEUVIMED entdecken
Open Access

Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice

Núria Rafel-Millan, Carles Bayod-Girón, Maria Pallarès-Masmitjà, Cristina Fernández-Avilés, Keilisa Figuereo-Moya, Ángel Edo, Miguel Chillón, Miquel Vila-Perelló, Silvia Frutos, Marc Güell

Molecular Therapy · 2026-10 · 34 (10) · 5697-5709

DOI: 10.1016/j.ymthe.2026.07.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Núria Rafel-Millan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; SpliceBio, 08028 Barcelona, Spain. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Laminin, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Agencia Estatal de Investigación, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several therapies using adeno-associated viruses (AAVs) as a gene delivery tool have received marketing approval in the past. However, potential applications of AAVs are limited by their restricted gene packaging capacities (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyLamininGenetic VectorsInteinsMuscular DystrophiesAnimalsMicePhenotypeDisease Models, AnimalHumansGene Therapy AgentsMuscle, Skeletal

Stichwörter der Autor:innen

AAVgene therapymuscular dystrophyprotein trans-splicingskeletal musclesplit inteins

Substanzen

Lamininlaminin alpha 2

Autor:innen und Institutionen

  • Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; SpliceBio, 08028 Barcelona, Spain.
  • Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
  • Department of Medicine and Life Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
  • Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
  • Institut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain.
  • Institut de Neurociènces (INc), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Vall D'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain; Institució Catalana de Recerca I Estudis Avançats, 08010 Barc…

Förderung

  • Agencia Estatal de Investigación
  • Generalitat de Catalunya

Zitieren

APA

Rafel-Millan, N., Bayod-Girón, C., Pallarès-Masmitjà, M., Fernández-Avilés, C., Figuereo-Moya, K., Edo, Á., Chillón, M., Vila-Perelló, M., Frutos, S., & Güell, M. (2026). Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice. Molecular Therapy, 34(10), 5697-5709. https://doi.org/10.1016/j.ymthe.2026.07.045

Vancouver

Rafel-Millan N, Bayod-Girón C, Pallarès-Masmitjà M, Fernández-Avilés C, Figuereo-Moya K, Edo Á, et al. Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice. Molecular Therapy. 2026;34(10):5697-5709. doi:10.1016/j.ymthe.2026.07.045

BibTeX
@article{RafelMillan2026,
  author = {Rafel-Millan, Núria and Bayod-Girón, Carles and Pallarès-Masmitjà, Maria and Fernández-Avilés, Cristina and Figuereo-Moya, Keilisa and Edo, Ángel and Chillón, Miguel and Vila-Perelló, Miquel and Frutos, Silvia and Güell, Marc},
  title = {Triple-AAV intein-mediated gene therapy ameliorates dystrophic phenotype in MDC1A mice},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {10},
  pages = {5697--5709},
  doi = {10.1016/j.ymthe.2026.07.045}
}
Kostenlos starten →